NEW YORK (360Dx) – NeoGenomics today reported a 4 percent year-over-year increase in its total third quarter revenues, as clinical testing revenues grew less than 1 percent. 

For the three months ending Sept. 30, total revenues rose to $63.1 million from $60.8 million in the year-ago period, but fell short of the consensus Wall Street estimate of $63.9 million. 

Clinical testing revenues inched up to $56.2 million from $55.7 million in Q3 2016, and pharma services revenues rose 38 percent to $6.9 million from $5.0 million a year ago. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.